Skip to main content
Top
Published in: International Journal of Hematology 1/2012

01-01-2012 | Original Article

Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation

Authors: Alain M. Ngoma, Kazuhiko Ikeda, Yuko Hashimoto, Kazuhiro Mochizuki, Hiroshi Takahashi, Hideki Sano, Hayato Matsumoto, Hideyoshi Noji, Syunnichi Saito, Atsushi Kikuta, Kazuei Ogawa, Mikio Ohtsuka, Masafumi Abe, Kenneth E. Nollet, Hitoshi Ohto

Published in: International Journal of Hematology | Issue 1/2012

Login to get access

Abstract

To elucidate the correlation between regulatory T cells (Tregs) and acute graft-versus-host disease (aGVHD) or cytomegalovirus infection following allogeneic bone marrow transplantation (allo-BMT), we evaluated either CD4+CD25high or FOXP3+ Treg-enriched cells in peripheral blood (PB) from 20 patients who received allo-BMT, and in biopsies of skin with aGVHD. Proportions of CD4+CD25highFOXP3+ cells in total lymphocytes, but not other types of T cells, were lower in patients who eventually developed grades II–IV aGVHD (n = 13) than in others (n = 7, P < 0.001). Proportions of CD62L+ cells in CD4+CD25high cells at day +30 were lower (P < 0.01) in patients who eventually showed cytomegalovirus viremia (n = 6) than in others (n = 14). Incidence of aGVHD (P < 0.05) or cytomegalovirus viremia (P < 0.05) was higher in patients without these complications, but with lower proportions of PB CD4+CD25highFOXP3+ cells at day +30 (n = 8) than in others (n = 8). However, in skin with aGVHD (n = 5), there was marked or slightly increased infiltration of CD8+ cells (P < 0.001) or CD3+FOXP3+ cells (P < 0.05), respectively, when compared with control (n = 5), resulting in threefold higher ratio of CD8+/CD3+FOXP3+ cells in aGVHD relative to controls (P < 0.05). Thus, impaired reconstitution of Tregs may be associated with aGVHD and CMV infection. Moreover, imbalance of Tregs and CD8+ cells may play a role in aGVHD tissue.
Literature
1.
go back to reference Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–86.PubMedCrossRef Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–86.PubMedCrossRef
2.
go back to reference Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29–52.PubMedCrossRef Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29–52.PubMedCrossRef
3.
go back to reference Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Res. 2000;9:299–306.CrossRef Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Res. 2000;9:299–306.CrossRef
4.
go back to reference Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.PubMedCrossRef Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.PubMedCrossRef
5.
go back to reference Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.PubMed
6.
go back to reference Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med. 1990;172:1701–8.PubMedCrossRef Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med. 1990;172:1701–8.PubMedCrossRef
7.
go back to reference Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced by elimination of T cell subset: Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985;161:72–87.PubMedCrossRef Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced by elimination of T cell subset: Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985;161:72–87.PubMedCrossRef
8.
go back to reference Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science. 2003;299:1057–61.PubMedCrossRef Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science. 2003;299:1057–61.PubMedCrossRef
9.
go back to reference Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.PubMedCrossRef Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.PubMedCrossRef
10.
go back to reference Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:337–42.PubMedCrossRef Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:337–42.PubMedCrossRef
11.
go back to reference Thorton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–90. Thorton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–90.
12.
go back to reference Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.PubMedCrossRef Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.PubMedCrossRef
13.
go back to reference Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420:502–7.PubMedCrossRef Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420:502–7.PubMedCrossRef
14.
go back to reference Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16:157–62.PubMedCrossRef Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16:157–62.PubMedCrossRef
15.
go back to reference Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4+CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401–6.PubMedCrossRef Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4+CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401–6.PubMedCrossRef
16.
go back to reference Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–9.PubMedCrossRef Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–9.PubMedCrossRef
17.
go back to reference Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220–6.PubMedCrossRef Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220–6.PubMedCrossRef
18.
go back to reference Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, et al. l-Selectin(hi) but not the l-selectin(lo) CD4+CD25+ regulatory T cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804–12.PubMedCrossRef Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, et al. l-Selectin(hi) but not the l-selectin(lo) CD4+CD25+ regulatory T cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804–12.PubMedCrossRef
19.
go back to reference Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201:1037–44.PubMedCrossRef Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201:1037–44.PubMedCrossRef
20.
go back to reference Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, et al. Critical role of CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood. 2005;106:3300–7.PubMedCrossRef Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, et al. Critical role of CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood. 2005;106:3300–7.PubMedCrossRef
21.
go back to reference Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood. 2004;103:2410–6.PubMedCrossRef Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood. 2004;103:2410–6.PubMedCrossRef
22.
go back to reference Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory T cells gene expression with graft-versus-host disease. Blood. 2004;104:2187–93.PubMedCrossRef Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory T cells gene expression with graft-versus-host disease. Blood. 2004;104:2187–93.PubMedCrossRef
23.
go back to reference Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552–60.PubMedCrossRef Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552–60.PubMedCrossRef
24.
go back to reference Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood. 2004;103:1140–6.PubMedCrossRef Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood. 2004;103:1140–6.PubMedCrossRef
25.
go back to reference Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–11.PubMedCrossRef Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–11.PubMedCrossRef
26.
go back to reference Meignin V, Peffault de Latour R, Zuber J, Régnault A, Mounier N, Lemaître F, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33:894–900.PubMedCrossRef Meignin V, Peffault de Latour R, Zuber J, Régnault A, Mounier N, Lemaître F, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33:894–900.PubMedCrossRef
27.
go back to reference Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed
28.
go back to reference Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.PubMedCrossRef Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.PubMedCrossRef
29.
go back to reference Kurihara T, Hayashi J, Ito A, Asai T. CMV antigenemia assay using indirect ALP-immunostaining in bone marrow transplant recipients. Transplant Proc. 1996;28:1750–3.PubMed Kurihara T, Hayashi J, Ito A, Asai T. CMV antigenemia assay using indirect ALP-immunostaining in bone marrow transplant recipients. Transplant Proc. 1996;28:1750–3.PubMed
30.
go back to reference Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, et al. Frequency of CD4+CD25highFOXP3+ regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:907–14.PubMedCrossRef Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, et al. Frequency of CD4+CD25highFOXP3+ regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:907–14.PubMedCrossRef
31.
go back to reference Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479–93.PubMedCrossRef Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479–93.PubMedCrossRef
32.
go back to reference Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, et al. Th17/Treg ratio in human graft-versus-host disease. Blood. 2010;116:1165–71.PubMedCrossRef Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, et al. Th17/Treg ratio in human graft-versus-host disease. Blood. 2010;116:1165–71.PubMedCrossRef
33.
go back to reference Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107:1717–23.PubMedCrossRef Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107:1717–23.PubMedCrossRef
34.
go back to reference Pastore D, Delia M, Mestice A, Perrone T, Carluccio P, Gaudio F, Giordano A, Rossi AR, Ricco A, Leo M, Liso V, Specchia G. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:550–7.PubMedCrossRef Pastore D, Delia M, Mestice A, Perrone T, Carluccio P, Gaudio F, Giordano A, Rossi AR, Ricco A, Leo M, Liso V, Specchia G. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:550–7.PubMedCrossRef
35.
go back to reference Le Blanc K, Barrett AJ, Schaffer M, Hägglund H, Ljungman P, Ringdén O, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant. 2009;15:1108–15.PubMedCrossRef Le Blanc K, Barrett AJ, Schaffer M, Hägglund H, Ljungman P, Ringdén O, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant. 2009;15:1108–15.PubMedCrossRef
Metadata
Title
Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation
Authors
Alain M. Ngoma
Kazuhiko Ikeda
Yuko Hashimoto
Kazuhiro Mochizuki
Hiroshi Takahashi
Hideki Sano
Hayato Matsumoto
Hideyoshi Noji
Syunnichi Saito
Atsushi Kikuta
Kazuei Ogawa
Mikio Ohtsuka
Masafumi Abe
Kenneth E. Nollet
Hitoshi Ohto
Publication date
01-01-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0976-7

Other articles of this Issue 1/2012

International Journal of Hematology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine